Markets
Alerts
F&O
MF
Reports
Screeners
Subscribe
Superstars
Portfolio
Watchlist
Insider Trades
Results
Data Downloader
Events Calendar
What's New
Explore
FAQs
Widgets
More
Search stocks
IND
USA
IND
IND
×
Close
IND
USA
Stocks
Futures & Options
Mutual Funds
News
Fundamentals
Reports
Corporate Actions
Alerts
Shareholding
Overview
Buy Sell Zone
F&O
Financials
News
All
News
Earnings Calls
Corporate Announcements
Research Reports
Reports
Technicals
Technicals
Share Price History
Delivery
Shareholding
Shareholding
Monthly MF Holdings
Bulk Block Deals
Insider Trading & SAST
Deals
Bulk Block Deals
Insider Trading & SAST
Corporate Actions
All
Dividend
Bonus
Split
Rights
Board Meetings
Alerts
About
Mankind Pharma Ltd.
NSE: MANKIND
|
BSE: 543904
|
ISIN: INE634S01028
|
Industry: Pharmaceuticals
|
Expensive Underperformer
2353.2000
-16.80
(
-0.71
%)
NSE
Jun 17, 2025
15:31 PM
Volume:
209.3K
Share on Facebook
Tweet
Share on LinkedIn
Share via Whatsapp
Mankind Pharma Ltd.
12 Mar 2025
2353.20
-0.71%
Mankind Pharma Launches Generic Version Of Empagliflozin Diabetes Medication
NDTV Profit
The launch follows the expiration of Boehringer Ingelheim's patent for Empagliflozin in India.
Mankind Pharma Ltd. has an
average target
of 2784.33 from 3 brokers.
More from Mankind Pharma Ltd.
Recommended
Five stocks to buy from analysts this week - June 17, 2025
The Baseline |
17 Jun 2025, 05:50PM
Market closes lower, CG Power bags a Rs 641 cr order from Power Grid for 765/400 kV transformers
Trendlyne Marketwatch |
17 Jun 2025, 03:54PM
Chart of the Week: FIIs raise bets in consumer-driven sectors over the year
The Baseline |
16 Jun 2025, 05:21PM